Aethlon Medical Names Dr. Robert H. Keller to HIV/AIDS Science Advisory Board.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that Robert H. Keller, M.D., M.C., FACP, AAHIVS, has been appointed to its newly established HIV/AIDS Science Advisory Board. Dr. Keller is the author of over 100 peer review research and clinical articles. He has served on the Editorial Boards of Diagnostic Immunology (1986-1990), Journal of Leukocyte Biology (1984-1986) and Interventions in Aging (2005-present). His many honors include the Humanitarian of the Year Award from the National Hemophilia Federation, and election to the Board of Governors of the Florida Chapter of the American Academy of HIV Medicine. Dr. Keller was also voted one of America's top physicians in internal medicine, immunology and hematology by the Consumer's Research Council of America.

"Dr. Keller has been caring for HIV patients since the inception of the AIDS pandemic," stated Aethlon CEO, James A. Joyce. "We are privileged to have access to his clinical insights and expertise," added Joyce. "Based on the response to our presentations at the XVI International AIDS Conference and the U.S. Conference on AIDS, we will establish an HIV-specific advisory board to help define and advance the clinical applications of our Hemopurifier(TM) in HIV therapy," concluded Joyce.

Dr. Keller is a pioneer in the field of immunology. He received his M.D. with honors in 1970 from Temple University in Philadelphia, Pa. From 1974-1976 he was a Fellow and Senior Fellow in the Department of Immunology at the Mayo Clinic in Rochester, N.Y., earning his Master of Science in Immunology from the same institution in 1976. During 1974-1976, he became Fellow and Senior Research Fellow in Immunology at the Mayo Clinic Foundation. In 1976, he was appointed Assistant Professor in Medicine at the University of Minnesota.

From 1977-1980, Dr. Keller was an Assistant Professor in the Hematology/Oncology section of the Department of Medicine at the Medical College of Wisconsin in Milwaukee, Wis. From 1979-1982, he was also a Clinical Associate Professor of Hematology, Immunology and Flow Cytometry at the Department of Health Services at the University of Wisconsin in Milwaukee, and from 1980-1982 was Director of Immunology at the Midwest Children's Cancer Center in the same city.

In 1986, Dr. Keller relocated to Hialeah, Fla., to serve as Associate Director of Research and Development at Coulter Immunology, a leading supplier of flow cytometers and reagents. Subsequently, he established his medical practice in Florida, and since 1998 has served as a Voluntary Adjunct Professor at the Miller School of Medicine, University of Miami, in Miami, Fla.

About Aethlon Medical

Aethlon Medical has developed the first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.